ATHA
Athira Pharma Inc.
$3.87
+$0.04(+1.04%)
36
Overall
--
Value
50
Tech
23
Quality
Market Cap
$15.05M
Volume
32.51K
52W Range
$2.20 - $8.26
Target Price
$0.50
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $20.0M | $64.0M | $88.9M | $127.1M | $96.8M | ||
| Research & Development | $13.3M | $42.8M | $61.5M | $93.8M | $70.7M | ||
| Research Expense | $13.3M | $42.8M | $61.5M | $93.8M | $70.7M | ||
| Selling, General & Administrative | $6.7M | $21.2M | $32.6M | $33.3M | $26.1M | ||
| General & Administrative Expenses | $6.7M | $21.2M | $32.6M | $33.3M | $26.1M | ||
| Salaries & Wages | -- | -- | -- | $10.6M | $11.0M | ||
| Depreciation & Amortization | $2.0K | $479.0K | $845.0K | $969.0K | $970.0K | ||
| Depreciation & Amortization | $2.0K | $479.0K | $845.0K | $969.0K | $970.0K | ||
| Other Operating Expenses | $85.0K | $323.0K | $-684.0K | $-1.5M | $-1.0M | ||
| OPERATING INCOME | |||||||
| Operating income | $-20.0M | $-64.0M | $-104.0M | $-125.5M | $-100.9M | ||
| EBITDA | $-19.6M | $-54.7M | $-88.0M | $-116.5M | $-95.7M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $367.0K | $3.0K | -- | -- | -- | ||
| Intinc | $124.0K | $337.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-243.0K | $334.0K | -- | -- | -- | ||
| Other Income/Expense | $1.3M | $-334.0K | $-6.8M | $-7.6M | $-4.0M | ||
| Other Special Charges | $-1.3M | $334.0K | $3.2M | $7.6M | $4.0M | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $2.9M | ||
| Special Income Charges | -- | -- | $-10.0M | $1.6M | $-4.1M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-19.6M | $-55.2M | $-88.9M | $-117.7M | $-96.9M | ||
| Pre-Tax Income | $-21.3M | $-63.7M | $-95.6M | $-117.8M | $-96.9M | ||
| NET INCOME | |||||||
| Net Income | $-20.0M | $-54.9M | $-95.6M | $-117.7M | $-96.9M | ||
| Net Income (Continuing Operations) | $-20.0M | $-54.9M | $-95.6M | $-117.7M | $-96.9M | ||
| Net Income (Discontinued Operations) | $-20.0M | $-54.9M | $-95.6M | $-117.7M | $-96.9M | ||
| Net Income (Common Stockholders) | $-20.0M | $-55.3M | $-95.6M | $-117.7M | $-96.9M | ||
| Normalized Income | -- | -- | -- | -- | $-89.0M | ||
| TOTALS | |||||||
| Total Expenses | $20.0M | $64.0M | $88.9M | $127.1M | $96.8M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $12.0M | $36.9M | $37.7M | $38.0M | $38.5M | ||
| Average Shares Outstanding (Diluted) | $12.0M | $36.9M | $37.7M | $38.0M | $38.5M | ||
| Shares Outstanding | $37.1M | $37.6M | $37.9M | $38.3M | $39.0M | ||
| Basic EPS | $-1.67 | $-1.49 | $-2.53 | $-3.09 | $-2.52 | ||
| Basic EPS (Continuing Operations) | $-1.67 | $-1.49 | $-2.53 | $-3.09 | $-2.52 | ||
| Diluted EPS | $-1.67 | $-1.49 | $-2.53 | $-3.09 | $-2.52 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.53 | $-3.09 | $-2.52 | ||
| OTHER METRICS | |||||||
| Net Income From Other Gains Losses | $1.3M | $8.8M | $5.2M | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | $10.0M | $-1.6M | $4.1M | ||
| Other Gand A | $6.7M | $21.2M | $32.6M | $33.3M | $26.1M | ||
| Restruct | -- | -- | -- | -- | $2.9M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATHA | $3.87 | +1.0% | 32.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |